Heterologous COVID-19 Vaccine Schedules in Pregnant Thai Women
Heterologous COVID-19 vaccination schedules using CoronaVac-BNT162b2 or ChAdOx1-BNT162b2 elicit immunogenicity on par with homologous BNT162b2 regimens in pregnant women, according to an open-label non-inferiority trial published in Human Vaccines & Immunotherapeutics. The study evaluated maternal and cord blood antibody levels alongside adverse events to assess whether mixed primary series offer viable alternatives in mRNA-limited vaccination settings. Local and systemic adverse events across the trial groups remained mild to moderate, with higher reactogenicity reported in the ChAdOx1-BNT162b2 schedule.
Mixed Schedules Transfer Immunity to Newborns
Researchers assessed serum antibody responses and maternal-fetal antibody transmission by comparing homologous and heterologous regimens. Data highlighted that cord blood antibody levels showed no discernible change across groups. These results suggest that mixed schedules can successfully transfer immunity to newborns while maintaining safety profiles comparable to standard mRNA-only series. The trial provides information regarding maternal-fetal immune transfer in pregnant populations receiving heterologous doses.
Commentary notes several limitations within the original trial design that restrict how broadly the findings can be applied. The study featured a relatively small sample size and did not measure the effectiveness of the various immunization schedules in preventing COVID-19 infection or associated consequences. Potential confounding variables such as underlying medical comorbidities, socioeconomic status, healthcare access, and unrecognized past asymptomatic infections were not taken into account in the study.
Clinical Studies Must Confirm Heterologous Immunization Effectiveness
Additional clinical studies are required to confirm the practical effectiveness and protection offered by heterologous immunization strategies in pregnant cohorts. Researchers note that future investigations must evaluate how genetic background and varying healthcare access influence individual immune responses, as the trial lacked a clear follow-up time. Until broader real-world effectiveness data becomes available, mixed primary series data may be used to optimize vaccination protocols in settings with fluctuating vaccine supplies.
Worth a look